fda changes to semaglutide shortage ends as sets deadline for compounders The FDA has approved a

Niacin, at pharmacologic doses, has historically been used to modify lipid profiles, though current guidelines no longer routinely recommend it for cardiovascular risk reduction

325(14): p

Its ability to stimulate growth hormone release results to increased muscle protein synthesis and greater retention of lean body mass while also supporting reduction of body fat

Several Canadian and international generic manufacturers have submitted applications to Health Canada, including: Sandoz - with multiple semaglutide formulation applications Teva - applications for various strengths Apotex - submissions currently under regulatory review Taro Pharmaceuticals - generic semaglutide applications Vimy Pharma - Canadian-manufactured generic applications Market Impact Considerations Industry analysts expect generic semaglutide to be priced significantly below current brand-name medications

Curtis said the chain is testing menu items such as Whopper Bites and protein-forward bowls, partly to accommodate the shifting tastes of GLP-1 users